Abstract
Aven expression has recently been identified as an anti-apoptotic protein. In this study, Aven expression in 91 children with acute lymphoblastic leukemia (ALL) was investigated for possible correlation with clinical features at diagnosis and treatment outcome. Aven expression was found to be higher in patients >or=10 years old or <1 year (P=0.003), and in patients with unfavorable cytogenetic abnormalities (P<0.001). Aven expression was also significantly higher in relapsed patients in the standard-risk group. Aven overexpression was an independent poor prognostic factor. These findings demonstrate that Aven expression can predict prognosis in childhood ALL.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adaptor Proteins, Signal Transducing / biosynthesis*
-
Adaptor Proteins, Signal Transducing / genetics*
-
Adolescent
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Apoptosis Regulatory Proteins / biosynthesis*
-
Apoptosis Regulatory Proteins / genetics*
-
Child
-
Child, Preschool
-
Chromosome Aberrations
-
Chromosomes, Human, Pair 11 / genetics
-
Chromosomes, Human, Pair 12 / genetics
-
Chromosomes, Human, Pair 21 / genetics
-
Chromosomes, Human, Pair 22 / genetics
-
Chromosomes, Human, Pair 9 / genetics
-
Cytogenetic Analysis / methods
-
Female
-
Gene Expression Profiling*
-
Humans
-
Infant
-
Male
-
Membrane Proteins / biosynthesis*
-
Membrane Proteins / genetics*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*
-
Predictive Value of Tests
-
Prognosis
-
Recurrence
-
Reverse Transcriptase Polymerase Chain Reaction / methods
-
Risk Factors
-
Treatment Outcome
Substances
-
AVEN protein, human
-
Adaptor Proteins, Signal Transducing
-
Apoptosis Regulatory Proteins
-
Membrane Proteins